Select All | Select None
You can now keep track of new articles from Journal of Pharmacology and Experimental Therapeutics on your personalized homepage!
Abstract Bortezomib has been introduced recently in the therapy of multiple myeloma (MM), a disease that is frequently associated with progressive renal failure. Because bortezomib-based therapy has been reported to lead to a rapid recovery of kidney function in patients with MM, we decided to...
Abstract The present study was designed to compare the anti-inflammatory and antioxidant effects of two antidepressant drugs, desipramine 10,11-dihydro-5-3-(methylamino) propyl-5 H -dibenz- b , f azepine monohydrochloride and fluoxetine N...
Abstract Activation of pancreatic stellate cells (PSCs) is the key process in the development of pancreatic fibrosis, a common feature of chronic pancreatitis and pancreatic cancer. In recent studies, curcumin has been shown to inhibit PSC proliferation via an extracellular signal-regulated...
Abstract Cholestasis causes hepatocyte death, possibly because of mitochondrial injury. This study investigated whether NIM811 ( N -methyl-4-isoleucine cyclosporine), an inhibitor of the mitochondrial permeability transition (MPT), attenuates cholestatic liver injury in vivo. Cholestasis was...
Abstract Elimination of hydrogen sulfide from glutathione (GSH) converts a well known cellular nucleophile to an electrophilic species, γ-glutamyldehydroalanylglycine (EdAG). We have found that a sulfonium metabolite formed from GSH and busulfan undergoes a facile β-elimination reaction to give...
Abstract Recent evidence suggests that the P2X 7 receptor may play a role in the pathophysiology of preclinical models of pain and inflammation. Therefore, pharmacological agents that target this receptor may potentially have clinical utility as anti-inflammatory and analgesic therapy. We...
Abstract We report the first small-molecule protease-activated receptor (PAR) 2 agonists, AC-55541 N -1-(3-bromo-phenyl)-eth-( E )-ylidene-hydrazinocarbonyl-(4-oxo-3,4-dihydro-phthalazin-1-yl)-methyl-benzamide and AC-264613 2-oxo-4-phenylpyrrolidine-3-carboxylic acid 1-(3-bromo-phenyl)-( E / Z...
Abstract Macitentan, also called Actelion-1 or ACT-064992 N -5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)-pyrimidin-4-yl- N ′-propylaminosulfonamide, is a new dual ET A /ET B endothelin (ET) receptor antagonist designed for tissue targeting. Selection of macitentan was based on...
Abstract Metabotropic glutamate subtype-5 receptors (mGluR5) are implicated in several neuropsychiatric disorders. Positron emission tomography (PET) with a suitable radioligand may enable monitoring of regional brain mGluR5 density before and during treatments. We have developed a new...
Abstract Epoxyeicosatrienoic acids (EETs) are derived from cytochrome P450-catalyzed epoxygenation of arachidonic acid and have emerged as important mediators of numerous biological effects. The major elimination pathway for EETs is through soluble epoxide hydrolase (sEH)-catalyzed metabolism to...
results per page
Save this article to read later. You can see your Read Later on your DeepDyve homepage.
To save an article, log in first, or sign up for a DeepDyve account if you don't already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don't already have one.
Read and print from thousands of top scholarly journals.
Sign up with Facebook
Sign up with Google
Already have an account? Log in
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don't already have one.